Amsterdam, 5 February 2007 – Elsevier will launch Biotechnology,
the Journal, as the official publication of the European Federation of
Biotechnology (EFB) in September 2007. Biotechnology, the Journal will be a
cross-disciplinary research and review journal aimed at an audience of
academic and commercial bioscientists who are interested not only in science
but also in its translation and use. The bi-monthly journal will be a platform
for peer-reviewed articles and editorial comments related to biotechnology.
Editor-in-Chief of the journal will be John Hodgson who was Editor of Trends
in Biotechnology and Senior Editor of Nature Biotechnology. Hodgson is one of
the founders of the biotech consultancy firm, Critical I. According to
Hodgson, Biotechnology, the Journal will have a global reach in content and
subscription base. "It is important for the credibility of Biotechnology, the
Journal that it publishes the best in science and reflects technical and
political discussion in an entirely international context. The journal will be
inclusive, reaching eastward and westward, seeking the excitement and
opportunity in the sciences, technologies and businesses behind
biotechnology".
The launch of this exciting journal is planned to coincide with the start of
ECB13, The European Congress on Biotechnology, which will be held from
September 16th – 19th in Barcelona, Spain. EFB Secretary General Christian
Suojanen comments, "We are extremely pleased to be able to launch the journal
with both John Hodgson and Elsevier as partners. Biotechnology, the Journal,
will seek to reflect the EFB’s recognition that the boundaries of science and
commerce do not stop at the borders of the European Union, and that it is
vital that Biotechnology, the Journal provides the global context that our
members need. We firmly believe that the journal will be a success and thus
aid in serving both our members and the life sciences community as a whole".
# # #
About the European Federation of Biotechnology
Established by
European scientists in 1978, the European Federation of Biotechnology (EFB) is
Europe’s non-profit federation of National Biotechnology Associations, Learned
Societies, Universities, Scientific Institutes, Biotech Companies and
Individuals, with 225 Institutional Members and 5,000 personal members in 56
countries working to promote biotechnology throughout Europe and beyond.
The mission of EFB is to advance the sustainable and beneficial use of the
life sciences, to promote research and innovation at the cutting edge of
biotechnology, to provide a forum for interdisciplinary and international
cooperation, to improve scientific education and to facilitate an informed
dialogue between scientists and the public.
The EFB has 13 Regional Branch Offices across Europe, one in Beijing and
another in development in Moscow. The Central Office is located in Barcelona,
Spain. 
www.efb-central.org
Every two years the EFB organizes the European Congress on Biotechnology. The
13th edition takes place in Barcelona 16-19 September 2007.
www.ecb13.eu
About Elsevier Society Publishing
Elsevier is committed to
building unique, long-lasting relationships to help societies achieve their
publishing goals and provide value-added member services. Elsevier partners
with more than 500 international learned societies, professional associations
and research institutes. To learn more, please visit the
Society
homepage on Elsevier.com.
About Elsevier
Elsevier is a world-leading publisher of
scientific, technical and medical information products and services. Working
in partnership with the global science and health communities, Elsevier’s
7,000 employees in over 70 offices worldwide publish more than 2,000 journals
and 1,900 new books per year, in addition to offering a suite of innovative
electronic products, such as
ScienceDirect,
MD Consult,
Scopus,
bibliographic databases, and online reference works.
Elsevier is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of
Reed Elsevier Group
plc, a world-leading publisher and information provider. Operating in the
science and medical, legal, education and business-to-business sectors, Reed
Elsevier provides high-quality and flexible information solutions to users,
with increasing emphasis on the Internet as a means of delivery. Reed
Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock
Exchange), RUK and ENL (New York Stock Exchange).
Media Contacts:
Dr. John Hodgson Kate Alzapiedi
+44
1223 307 544 +31 20 485 3836
john.hodgson@criticali.net
k.alzapiedi@elsevier.com
